ongitudinal analysis of RCC-specific immunity in renal cell carcinoma patients

• Conditions: hypernephroma; kidney cancer; 10038430

• Registration Number: NL-OMON45138
• Lead Sponsor: ederlands Kanker Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 600

Inclusion Criteria

Histologically or cytologically proven renal cell carcinoma
Measurable metastatic lesion(s), according to RECIST 1.1 criteria
Metastatic lesion(s) of which a histological biopsy can safely be obtained
Age above 18 years
Performance score: WHO 0, 1 or 2
Written informed consent

Exclusion Criteria

see inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To study the longitudinal effects of treatment (e.g. anti-CTLA4, BRAF<br /><br>inhibition, and other treatments) for advanced stage renal cell carcinoma on<br /><br>tumor material obtained by surgical removal/biopsies and on peripheral blood<br /><br>components.<br /><br><br /><br>To find predictive markers and/or prognostic markers in biopsied tumor material<br /><br>and peripheral blood<br /><br><br /><br>To improve current TIL expansion protocols</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>